Inherited genetic markers for thrombophilia in northeastern Iran (a clinical-based report)

• Published in: Reports of biochemistry and molecular biology Vol. 2; no. 2; pp. 76 - 82
• Main Authors: Keify, Fatemeh, Azimi-Nezhad, Mohsen, Zhiyan-Abed, Narges, Nasseri, Mojila, Abbaszadegan, Mohammad Reza
• Format: Journal Article
• Language: English
• Published: Iran Varastegan Institute for Medical Sciences 01.04.2014
• Subjects: Factor II; Factor V; MTHFR; Original; PAI; Thrombophilia; Thrombophilic markers; Factor V; Thrombophilia; MTHFR; PAI; Factor II; Thrombophilic markers
• ISSN: 2322-3480; 2322-3480

Thrombophilia is a main predisposition to thrombosis due to a procoagulant state. Several point mutations play key roles in blood-clotting disorders, which are grouped under the term thrombophilia. These thrombophilic mutations are methylenetetrahydrofolate reductase (MTHFR, C677T, and A1298C), factor V Leiden (G1691A), prothrombin gene mutation (factor II, G20210A), and plasminogen activator inhibitor (PAI). In the present study, we assessed the prevalence of the above thrombophilia markers in patients with recurrent pregnancy loss or first and second trimester abortions, infertility, and failed in vitro fertilization (IVF). This study was conducted among 457 cases those were referred to detect the inherited genetic markers for thrombophilia. Markers for MTHFR, Factor II, and Factor V were assessed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP), and PAI was assessed by Amplification Refractory Mutation System (ARMS-PCR). Two hundred sixty cases (56.89%) were diagnosed as having at least one thrombophilia marker, whereas 197 cases (43.11%) had no thrombophilia markers and were normal. According to the current study, the pattern of abnormal genetic markers for thrombophilia in northeastern Iran demonstrates the importance of genetic evaluations in patients who show clinical abnormalities with recurrent spontaneous abortion (RSA) or other serious obstetric complications.